Biotech Values

[jbog]

They rarely receive a large sum. Their royalties normally are in low single digits.

Sometimes they luck out. In 2019 they sold off their Novartis Promacta royalties for $850 million.

When Viking couldn't afford their products years ago Viking elected to give Ligand stock while Ligand also funded them. They've sold those off over the years probably gaining $500 to $700 million. They have just sold a > million shares and still hold 3.5%of the viking

Ligand could be one of the best management teams in the biospace.